Type 2 immunopathology is a cardinal feature of allergic diseases and involves cooperation between adaptive immunity and innate effector responses. Virtually all cell types relevant to this pathology generate leukotriene and/or prostaglandin mediators that derive from arachidonic acid, express receptors for such mediators, or both. Recent studies highlight prominent functions for these mediators in communication between the innate and adaptive immune systems, as well as amplification or suppression of type 2 effector responses. This review focuses on recent advances and insights, and highlights existing and potential therapeutic applications of drugs that target these mediators or their receptors, with a special emphasis on their regulation of the innate and adaptive lymphocytes relevant to type 2 immunopathology.
Keywords: Innate type 2 immunopathology; allergic inflammation; aspirin-exacerbated respiratory disease; asthma; cysteinyl leukotrienes; eicosanoids; eosinophilic esophagitis; innate immune cells; innate lymphoid cells; prostacyclins; prostaglandins.
Copyright © 2018. Published by Elsevier Inc.